Graves' ophthalmopathy: Natural history and treatment outcomes

Swiss Medical Weekly

Volumn 131, Issue 41-42, 2001, Pages 603-609

  Noth, D ^a  

^a Medizinische Klinik   (Switzerland)

Author keywords

Graves' disease; Graves' ophthalmopathy; Thyreotoxicosis; Treatment outcome

Indexed keywords

CORTICOSTEROID; PREDNISONE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CORTICOSTEROID THERAPY; DECOMPRESSION SURGERY; DISEASE COURSE; DISEASE SEVERITY; EYE DISEASE; FEMALE; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; IRRADIATION; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; TREATMENT OUTCOME;

EID: 0035923177     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Pathogenesis of immunogenic hyperthyroidism and endocrine orbitopathy
2. TSH receptor transcripts and TSH receptor-like immunoreactivity in orbital and pretibial fibroblasts of patients with Graves' ophthalmopathy and pretibial myxedema
3. Pathogenesis of Graves' ophthalmopathy
4. Clinical review 13: Diagnosis and management of Graves' ophthalmopathy
5. Diagnosis and management of endocrine ophthalmopathy
6. Dysthyroid ophthalmopathy: Orbital evaluation with B-scan ultrasonography
7. Computed tomography in Graves' ophthalmopathy
8. Ultrasonographic evidence of a consistent orbital involvement in Graves' disease
9. Ophthalmic Graves's disease: Natural history and detailed thyroid function studies
10. Identification of subgroups of euthyroid Graves' ophthalmopathy
11. Ophthalmic Graves' disease. Diagnosis and pathogenesis
12. The full length and splice variant thyrotropin receptor is expressed exclusively in skeletal muscle of extraocular origin: A link to the pathogenesis of Graves' ophthalmopathy
13. Involvement of the orbital fibroblast and TSH receptor in the pathogenesis of Graves' ophthalmopathy
14. Expression of thyrotropin-receptor mRNA in healthy and Graves' disease retro-orbital tissue
15. Effect of tumor necrosis factor-alpha, interferon-gamma, and transforming growth factor-beta on adipogenesis and expression of thyrotropin receptor in human orbital preadipocyte fibroblasts
16. Adipogenesis in thyroid eye disease
17. Both Th1- and Th2-derived cytokines in serum are elevated in Graves' ophthalmopathy
18. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy
19. Cigarette smoking and the thyroid
20. Smoking and risk of Graves' disease
21. Association between Graves' ophthalmopathy and smoking
22. More on smoking habits and Graves' ophthalmopathy
23. Is endocrine ophthalmopathy related to smoking?
24. Diagnostic criteria for Graves' ophthalmopathy
25. Classification of the eye changes of Graves' disease
26. Age and gender influence the severity of thyroid-associated ophthalmopathy: A study of 101 patients attending a combined thyroid-eye clinic
27. Studies on the occurrence of ophthalmopathy in Graves' disease
28. Temporal relationship between onset of Graves' ophthalmopathy and diagnosis of thyrotoxicosis
29. Patients with endocrine ophthalmopathy not associated with overt thyroid disease have multiple thyroid immunological abnormalities
30. Graves' ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: Prevalence, natural history, and thyrotropin receptor antibody levels
31. The study of visual evoked potentials in patients with thyroid-associated ophthalnopathy identifies asymptomatic optic nerve involvement
32. Severe endocrine ophthalmopathy. A review with case reports
33. Dysthyroid optic neuropathy. The crowded orbital apex syndrome
34. Early diagnosis of Graves' optic neuropathy using visual evoked responses
35. Ophthalmologic aspects of thyroid-related orbitopathy
36. What the internist should know about the ophthalmopathy of Graves' disease
37. Natural history of thyroid associated ophthalmopathy
38. Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy
39. Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy
40. Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: Comparison with systemic corticosteroids alone
41. High-dose intravenous steroid pulse therapy in thyroid-associated ophthalmopathy
42. Intravenous methylprednisolone in the treatment of Graves' ophthalmopathy
43. Supervoltage orbital radiotherapy for Graves' ophthalmopathy
44. Clinical outcomes of orbital irradiation combined with or without systemic high-dose or pulsed corticosteroids for Graves' ophthalmopathy
45. The course of endocrine ophthalmopathy during antithyroid therapy in a prospective study
46. The presentation and management of endocrine ophthalmopathy
47. Thyroid-associated eye disease: Clinical management
48. Orbital decompression for severe dysthyroid eye disease
49. Dysthyroid optic neuropathy. Clinical profile and rationale for management
50. Strabismus after balanced medial plus lateral wall versus lateral wall only orbital decompression for dysthyroid orbitopathy